Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis

Bibliography

• ABar-Or, APachner, FMenguy-Vacheron, et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014;74:659-74
   PubMed Web of Science ®Google Scholar
• FCBreedveld, JMDayer. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000;59:841-9
   PubMed Web of Science ®Google Scholar
• HMCherwinski, RGCohn, PCheung, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995;275:1043-9
   PubMed Web of Science ®Google Scholar
• SGreene, KWatanabe, JBraatz-Trulson, et al. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995;50:861-7
   PubMed Web of Science ®Google Scholar
• LLi, JLiu, TDelohery, et al. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. J Neuroimmunol 2013;265:82-90
   PubMed Web of Science ®Google Scholar
• SCJameson. Maintaining the norm: T-cell homeostasis. Nat Rev Immunol 2002;2:547-56
   PubMed Web of Science ®Google Scholar
• GKGrimble. Dietary nucleotides and gut mucosal defence. Gut 1994;35:S46-51
   PubMed Web of Science ®Google Scholar
• NHailJr, PChen, JJKepa, et al. Evidence supporting a role for dihydroorotate dehydrogenase, bioenergetics, and p53 in selective teriflunomide-induced apoptosis in transformed versus normal human keratinocytes. Apoptosis 2012;17:258-68
   PubMed Web of Science ®Google Scholar
• TLimsakun, FMenguy-Vacheron. Pharmacokinetics of oral teriflunomide, a novel oral disease-modifying agent under investigation for the treatment of multiple sclerosis. 62nd Annual Meeting of the American Academy of Neurology (AAN); April 10–17, 2010; Toronto, ON, Canada
   Google Scholar
• European Medicines Agency. Aubagio: EPAR: product information 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002514/WC500148682.pdf [Last accessed 20 October 2014]
   Google Scholar
• MDWiese, ARowland, TMPolasek, et al. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. Expert Opin Drug Metab Toxicol 2013;9:1025-35
   PubMed Web of Science ®Google Scholar
• SMDe, GStraface, ACavaliere, et al. Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann Rheum Dis 2005;64:1096-7
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Tecfidera: EPAR: product information 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002601/WC500162069.pdf [Last accessed 14 October 2014]
   Google Scholar
• European Medicines Agency. Gilenya: EPAR: product information 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf [Last accessed 14 October 2014]
   Google Scholar
• TRispens, AVennegoor, GJWolbink, et al. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler 2012;18:899-901
   PubMed Web of Science ®Google Scholar
• PWO’Connor, DLi, MSFreedman, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894-900
   PubMed Web of Science ®Google Scholar
• PO’Connor, JSWolinsky, CConfavreux, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303
   PubMed Web of Science ®Google Scholar
• CConfavreux, PO’Connor, GComi, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:247-56
   PubMed Web of Science ®Google Scholar
• PVermersch, ACzlonkowska, LMGrimaldi, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2014;20:705-16
   PubMed Web of Science ®Google Scholar
• AEMiller, JSWolinsky, LKappos, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:977-86
   PubMed Web of Science ®Google Scholar
• TLeist, MFreedman, LKappos, et al. Pooled safety data from three placebo-controlled teriflunomide studies. 29th ECTRIMS meeting, October 2-5, 2013; Copenhagen, Denmark
   Google Scholar
• CConfavreux, DKLi, MSFreedman, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 2012;18(9):1278-89
   PubMed Web of Science ®Google Scholar
• MFreedman, JSWolinsky, GComi, et al. Safety and efficacy of teriflunomide for up to 9 years in relapsing forms of multiple sclerosis: Update of the TEMSO extension trial. 66th Annual Meeting of the American Academy of Neurology (AAN); April 26 - May 3, 2014; Philadelphia, PA, USA
   Google Scholar
• FDA Approved labeling text. 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202992s000lbl.pdf [Last accessed 28 October 2014]
   Google Scholar
• ASartori, DCarle, MSFreedman. Teriflunomide: a novel oral treatment for relapsing multiple sclerosis. Expert Opin Pharmacother 2014;15:1019-27
   PubMed Web of Science ®Google Scholar
• MFreedman, CConfavreux, GComi, et al. Hair thinning associated with teriflunomide therapy is manageable. Fourth Cooperative Meeting of CMSC and ACTRIMS; May 30 - June 2, 2012; San Diego, CA, USA
   Google Scholar
• JSSmolen, JRKalden, DLScott, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66
   PubMed Web of Science ®Google Scholar
• ABar-Or, MSFreedman, MKremenchutzky, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology 2013;81:552-8
   PubMed Web of Science ®Google Scholar
• HIKeen, PGConaghan, SETett. Safety evaluation of leflunomide in rheumatoid arthritis. Expert Opin Drug Saf 2013;12:581-8
   PubMed Web of Science ®Google Scholar
• RABonnel, DJGraham. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 2004;75:580-5
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: new boxed warning for severe liver injury with arthritis drug Arava (leflunomide). Available from: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218679.htm [Last accessed 13 July 2010]
   Google Scholar
• SSuissa, MHudson, PErnst. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006;54:1435-9
   PubMed Web of Science ®Google Scholar
• GBloomgren, SRichman, CHotermans, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80
   PubMed Web of Science ®Google Scholar
• KWarnatz, HHPeter, MSchumacher, et al. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis 2003;62:50-7
   PubMed Web of Science ®Google Scholar
• MRahmlow, EAShuster, JDominik, et al. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol 2008;65:1538-9
   PubMed Web of Science ®Google Scholar
• DBClifford, BAnces, CCostello, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011;68:1156-64
   PubMed Web of Science ®Google Scholar
• RLBrent. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 2001;63:106-12
   PubMedGoogle Scholar
• RFukushima, SKanamori, MHirashiba, et al. Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Reprod Toxicol 2007;24:310-16
   PubMed Web of Science ®Google Scholar
• CDChambers, DLJohnson, LKRobinson, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010;62:1494-503
   PubMed Web of Science ®Google Scholar
• MCassina, DLJohnson, LKRobinson, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 2012;64:2085-94
   PubMed Web of Science ®Google Scholar
• LJHenson, MBenamor, PTruffinet, BKieseier. Updated pregnancy outcomes in patients and partners of patients in the teriflunomide clinical trial program. 66th Annual Meeting of the American Academy of Neurology (AAN); April 26 - May 3, 2014; Philadelphia, PA, USA
   Google Scholar
• BKieseier, MBenamor, PTruffinet, et al. Pregnancy outcomes for female patients and partners of male patients in the teriflunomide clinical development program. Joint ACTRIMS-ECTRIMS Meeting, September 10-13, 2014; Boston, MA, USA
   Google Scholar
• LDavenport, ACzich, STurpault. Teriflunomide: non-clinical evaluation demonstrates no effect on sperm DNA or male fertility. 66th Annual Meeting of the American Academy of Neurology (AAN); April 26 - May 3, 2014; Philadelphia, PA, USA
   Google Scholar
• YDFragoso. Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation. Expert Opin Drug Saf 2014;13(12):1743-8
   PubMed Web of Science ®Google Scholar
• UErmis, JWeis, JBSchulz. PML in a patient treated with fumaric acid. N Engl J Med 2013;368:1657-8
   PubMed Web of Science ®Google Scholar
• UErmis, JWeis, JBSchulz. Case reports of PML in patients treated for psoriasis. N Engl J Med 2013;369(11):1081
   PubMed Web of Science ®Google Scholar
• BWvan Oosten, JKillestein, FBarkhof, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013;368:1658-9
   PubMed Web of Science ®Google Scholar
• MTSweetser, KTDawson, CBozic. Manufacturer’s response to case reports of PML. N Engl J Med 2013;368:1659-61
   PubMed Web of Science ®Google Scholar
• NPutzki, DClifford, DBischofl, et al. Characteristics of PML cases in multiple sclerosis patients switching to fingolimod from natalizumab. Joint ACTRIMS-ECTRIMS Meeting; September 10-13, 2014; Boston, MA, USA
   Google Scholar
• APSempere, JGimenez-Martinez. Safety considerations when choosing the appropriate treatment for patients with multiple sclerosis. Expert Opin Drug Saf 2014;13:1287-9
   PubMed Web of Science ®Google Scholar
• RGold, TPhilips, EHavrdova, et al. BG-12 (Dimethyl fumarate) and pregnancy: Preclinical and clinical data from the clinical development program. 65th Annual Meeting of the American Academy of Neurology (AAN); March 16-23, 2013; San Diego, CA, USA
   Google Scholar
• GKarlsson, GFrancis, GKoren, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 2014;82:674-80
   PubMed Web of Science ®Google Scholar
• AMLanger-Gould. The pill times 2: what every woman with multiple sclerosis should know. Neurology 2014;82:654-5
   PubMed Web of Science ®Google Scholar
• RGold, LKappos, DLArnold, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
   PubMed Web of Science ®Google Scholar
• LKappos, EWRadue, PO’Connor, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• MSFreedman, JSWolinsky, BWamil, et al. Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial. Neurology 2012;78:1877-85
   PubMed Web of Science ®Google Scholar
• MFreedman, JWollinsky, GFrangin, et al. Oral teriflunomide or placebo added to glatiramer acetate for 6 months in patients with relapsing multiple sclerosis: Safety and efficacy results. 62nd Annual Meeting of the American Academy of Neurology (AAN); April 10–17, 2010; Toronto, ON, Canada
   Google Scholar
• CENeville, JMcNally. Maternal exposure to leflunomide associated with blindness and cerebral palsy. Rheumatology (Oxford) 2007;46:1506
   PubMed Web of Science ®Google Scholar
• BKraemer, HAbele, MHahn, et al. A successful pregnancy in a patient with Takayasu’s arteritis. Hypertens Pregnancy 2008;27:247-52
   PubMed Web of Science ®Google Scholar
• MSayarlioglu, MSahin, GYCetin, et al. Maternal exposure to leflunomide and methotrexate in a patient with adult-onset Still's disease. Rheumatology (Oxford) 2010;49:1787-9
   PubMed Web of Science ®Google Scholar
• AGarcia-Enguidanos, MECalle, JValero, et al. Risk factors in miscarriage: a review. Eur J Obstet Gynecol Reprod Biol 2002;49:111-9
   Google Scholar